XGN Insider Trading

Insider Ownership Percentage: 26.10%
Insider Buying (Last 12 Months): $145,866.97
Insider Selling (Last 12 Months): $660,000.00

Exagen Insider Trading History Chart

This chart shows the insider buying and selling history at Exagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Exagen Share Price & Price History

Current Price: $4.27
Price Change: Price Decrease of -0.16 (-3.61%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for XGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$4.27Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Exagen (NASDAQ:XGN)

75.25% of Exagen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$22ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
Exagen logo
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Read More on Exagen

Today's Range

Now: $4.27
Low: $3.88
High: $4.41

50 Day Range

MA: $3.90
Low: $2.85
High: $5.33

52 Week Range

Now: $4.27
Low: $1.30
High: $6.22

Volume

75,699 shs

Average Volume

84,619 shs

Market Capitalization

$76.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Who are the company insiders with the largest holdings of Exagen?

Exagen's top insider investors include:
  1. Nmsic Co-Investment Fund, LP (Major Shareholder)
  2. James L L Tullis (Major Shareholder)
  3. John Aballi (CEO)
  4. Kamal Adawi (CFO)
Learn More about top insider investors at Exagen.

Who are the major institutional investors of Exagen?

Exagen's top institutional investors include:
  1. Penbrook Management LLC — 0.22%
Learn More about top institutional investors of Exagen stock.

Which major investors are selling Exagen stock?

During the previous quarter, XGN stock was sold by these institutional investors:
  1. Penbrook Management LLC